These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 32739228)

  • 21. Value of 3-Tesla multiparametric magnetic resonance imaging and targeted biopsy for improved risk stratification in patients considered for active surveillance.
    Pessoa RR; Viana PC; Mattedi RL; Guglielmetti GB; Cordeiro MD; Coelho RF; Nahas WC; Srougi M
    BJU Int; 2017 Apr; 119(4):535-542. PubMed ID: 27500389
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Obesity is associated with risk of progression for low-risk prostate cancers managed expectantly.
    Bhindi B; Kulkarni GS; Finelli A; Alibhai SM; Hamilton RJ; Toi A; van der Kwast TH; Evans A; Hersey K; Jewett MA; Zlotta AR; Trachtenberg J; Fleshner NE
    Eur Urol; 2014 Nov; 66(5):841-8. PubMed ID: 24954793
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Magnetic Resonance Imaging in Active Surveillance (MRIAS) Trial: Use of Baseline Multiparametric Magnetic Resonance Imaging and Saturation Biopsy to Reduce the Frequency of Surveillance Prostate Biopsies.
    Amin A; Scheltema MJ; Shnier R; Blazevski A; Moses D; Cusick T; Siriwardena A; Yuen B; van Leeuwen PJ; Haynes AM; Matthews J; Brenner P; O'Neill G; Yuen C; Delprado W; Stricker P; Thompson J
    J Urol; 2020 May; 203(5):910-917. PubMed ID: 31825297
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Detection rate for significant cancer at confirmatory biopsy in men enrolled in Active Surveillance protocol: 20 cores vs 30 cores vs MRI/TRUS fusion prostate biopsy.
    Pepe P; Cimino S; Garufi A; Priolo G; Russo GI; Giardina R; Reale G; Barbera M; Panella P; Pennisi M; Morgia G
    Arch Ital Urol Androl; 2016 Dec; 88(4):300-303. PubMed ID: 28073197
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A multi-institutional evaluation of active surveillance for low risk prostate cancer.
    Eggener SE; Mueller A; Berglund RK; Ayyathurai R; Soloway C; Soloway MS; Abouassaly R; Klein EA; Jones SJ; Zappavigna C; Goldenberg L; Scardino PT; Eastham JA; Guillonneau B
    J Urol; 2013 Jan; 189(1 Suppl):S19-25; discussion S25. PubMed ID: 23234624
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk prediction tool for grade re-classification in men with favourable-risk prostate cancer on active surveillance.
    Mamawala MM; Rao K; Landis P; Epstein JI; Trock BJ; Tosoian JJ; Pienta KJ; Carter HB
    BJU Int; 2017 Jul; 120(1):25-31. PubMed ID: 27469419
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stability of a 17-Gene Genomic Prostate Score in Serial Testing of Men on Active Surveillance for Early Stage Prostate Cancer.
    Cedars BE; Washington SL; Cowan JE; Leapman M; Tenggara I; Chan JM; Cooperberg MR; Carroll PR
    J Urol; 2019 Oct; 202(4):696-701. PubMed ID: 30958742
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of immediate confirmatory prostate biopsy to ensure accurate eligibility for active surveillance.
    Motamedinia P; RiChard JL; McKiernan JM; DeCastro GJ; Benson MC
    Urology; 2012 Nov; 80(5):1070-4. PubMed ID: 23107398
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Optimization of prostate biopsy in patients considered for active surveillance. The role of the confirmatory biopsy and transperineal techniques.
    Fernandez Gomez JM; Garcia Rodriguez J
    Arch Esp Urol; 2014 Jun; 67(5):409-18. PubMed ID: 24914840
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Extended followup and risk factors for disease reclassification in a large active surveillance cohort for localized prostate cancer.
    Welty CJ; Cowan JE; Nguyen H; Shinohara K; Perez N; Greene KL; Chan JM; Meng MV; Simko JP; Cooperberg MR; Carroll PR
    J Urol; 2015 Mar; 193(3):807-11. PubMed ID: 25261803
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcomes of Scheduled vs For-Cause Biopsy Regimens for Prostate Cancer Active Surveillance.
    Al-Tartir T; Murekeyisoni C; Attwood K; Badkhshan S; Mehedint D; Safwat M; Guru K; Mohler JL; Kauffman EC
    J Urol; 2016 Oct; 196(4):1061-8. PubMed ID: 27157375
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Active Surveillance of Grade Group 1 Prostate Cancer: Long-term Outcomes from a Large Prospective Cohort.
    Tosoian JJ; Mamawala M; Epstein JI; Landis P; Macura KJ; Simopoulos DN; Carter HB; Gorin MA
    Eur Urol; 2020 Jun; 77(6):675-682. PubMed ID: 31918957
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of Subsequent Biopsies on Comprehensive Health Related Quality of Life in Patients with and without Prostate Cancer.
    Burns JF; Hurwitz LM; Levie KE; Caumont F; Brand TC; Rosner IL; Stroup S; Musser JE; Cullen J; Porter CR
    J Urol; 2019 May; 201(5):916-922. PubMed ID: 30676475
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MRI/US fusion prostate biopsy in men on active surveillance: Our experience.
    Lacetera V; Antezza A; Papaveri A; Cappa E; Cervelli B; Gabrielloni G; Montesi M; Morcellini R; Parri G; Recanatini E; Beatrici V
    Arch Ital Urol Androl; 2021 Mar; 93(1):88-91. PubMed ID: 33754618
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of Pathological and Oncologic Outcomes of Favorable Risk Gleason Score 3 + 4 and Low Risk Gleason Score 6 Prostate Cancer: Considerations for Active Surveillance.
    Gearman DJ; Morlacco A; Cheville JC; Rangel LJ; Karnes RJ
    J Urol; 2018 May; 199(5):1188-1195. PubMed ID: 29225057
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adherence to pelvic lymph node dissection recommendations according to the National Comprehensive Cancer Network pelvic lymph node dissection guideline and the D'Amico lymph node invasion risk stratification.
    Leyh-Bannurah SR; Budäus L; Zaffuto E; Pompe RS; Bandini M; Briganti A; Montorsi F; Schiffmann J; Shariat SF; Fisch M; Chun F; Huland H; Graefen M; Karakiewicz PI
    Urol Oncol; 2018 Feb; 36(2):81.e17-81.e24. PubMed ID: 29248430
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Value of an Extensive Transrectal Repeat Biopsy with Anterior Sampling in Men on Active Surveillance for Low-risk Prostate Cancer: A Comparison from the Randomised Study of Active Monitoring in Sweden (SAMS).
    Bratt O; Holmberg E; Andrén O; Carlsson S; Drevin L; Johansson E; Josefsson A; Nyberg M; Sandberg J; Stattin P; Robinsson D
    Eur Urol; 2019 Oct; 76(4):461-466. PubMed ID: 30878303
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cumulative Cancer Locations is a Novel Metric for Predicting Active Surveillance Outcomes: A Multicenter Study.
    Erickson AM; Luzzago S; Semjonow A; Vasarainen H; Laajala TD; Musi G; de Cobelli O; Mirtti T; Rannikko A
    Eur Urol Oncol; 2018 Sep; 1(4):268-275. PubMed ID: 31100247
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Understanding the Performance of Active Surveillance Selection Criteria in Diverse Urology Practices.
    Hawken SR; Womble PR; Herrel LA; Ye Z; Linsell SM; Hurley PM; Montie JE; Miller DC;
    J Urol; 2015 Nov; 194(5):1253-7. PubMed ID: 25981805
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Role of Multiparametric Magnetic Resonance Imaging/Ultrasound Fusion Biopsy in Active Surveillance.
    Ma TM; Tosoian JJ; Schaeffer EM; Landis P; Wolf S; Macura KJ; Epstein JI; Mamawala M; Carter HB
    Eur Urol; 2017 Feb; 71(2):174-180. PubMed ID: 27236496
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.